ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.49Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $334,847,904.00
EPSttm : -0.98
Allogene Therapeutics, Inc.
$1.49
0.00%$0.00000000000000Float Short %
11.26
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
-0.03
EPS Last/This Y
0.38
EPS This/Next Y
0.03
Price
1.5
Target Price
7.6
Analyst Recom
1.6
Performance Q
1.36
Relative Volume
1.14
Beta
0.6
Ticker: ALLO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-10 | ALLO | 1.48 | 0.12 | 0.50 | 3530 |
| 2025-12-11 | ALLO | 1.545 | 0.12 | 0.21 | 3636 |
| 2025-12-12 | ALLO | 1.51 | 0.12 | 0.00 | 3666 |
| 2025-12-15 | ALLO | 1.465 | 0.12 | 0.17 | 3669 |
| 2025-12-16 | ALLO | 1.54 | 0.12 | 0.20 | 3673 |
| 2025-12-17 | ALLO | 1.42 | 0.10 | 0.00 | 3817 |
| 2025-12-18 | ALLO | 1.42 | 0.10 | 10.00 | 3832 |
| 2025-12-19 | ALLO | 1.4 | 0.10 | 0.05 | 3840 |
| 2025-12-22 | ALLO | 1.465 | 0.12 | 0.06 | 3267 |
| 2025-12-23 | ALLO | 1.365 | 0.11 | 0.00 | 3438 |
| 2025-12-26 | ALLO | 1.385 | 0.10 | 0.00 | 3661 |
| 2025-12-29 | ALLO | 1.38 | 0.11 | 0.00 | 3650 |
| 2025-12-30 | ALLO | 1.305 | 0.11 | 0.00 | 3629 |
| 2025-12-31 | ALLO | 1.37 | 0.09 | 0.00 | 4281 |
| 2026-01-02 | ALLO | 1.355 | 0.09 | 0.01 | 4299 |
| 2026-01-05 | ALLO | 1.355 | 0.09 | 0.00 | 4391 |
| 2026-01-06 | ALLO | 1.405 | 0.09 | 0.00 | 4414 |
| 2026-01-07 | ALLO | 1.49 | 0.08 | 0.29 | 4935 |
| 2026-01-08 | ALLO | 1.49 | 0.08 | 0.52 | 5045 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-10 | ALLO | 1.49 | 20.3 | - | -0.94 |
| 2025-12-11 | ALLO | 1.55 | 20.3 | - | -0.94 |
| 2025-12-12 | ALLO | 1.51 | 20.3 | - | -0.94 |
| 2025-12-15 | ALLO | 1.47 | 20.3 | - | -0.94 |
| 2025-12-16 | ALLO | 1.47 | 20.3 | - | -0.94 |
| 2025-12-17 | ALLO | 1.43 | 20.3 | - | -0.94 |
| 2025-12-18 | ALLO | 1.42 | 20.3 | - | -0.94 |
| 2025-12-19 | ALLO | 1.40 | 20.3 | - | -0.94 |
| 2025-12-22 | ALLO | 1.48 | 20.3 | - | -0.94 |
| 2025-12-23 | ALLO | 1.37 | 20.3 | - | -0.94 |
| 2025-12-26 | ALLO | 1.38 | 20.3 | - | -0.94 |
| 2025-12-29 | ALLO | 1.38 | 20.3 | - | -0.94 |
| 2025-12-30 | ALLO | 1.30 | 20.3 | - | -0.94 |
| 2025-12-31 | ALLO | 1.37 | 20.3 | - | -0.94 |
| 2026-01-02 | ALLO | 1.36 | 20.3 | - | -0.94 |
| 2026-01-05 | ALLO | 1.35 | 20.3 | - | -0.94 |
| 2026-01-06 | ALLO | 1.40 | 20.3 | - | -0.94 |
| 2026-01-07 | ALLO | 1.50 | 20.3 | - | -0.94 |
| 2026-01-08 | ALLO | 1.50 | 20.3 | - | -0.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-10 | ALLO | -0.11 | -9.56 | 11.71 |
| 2025-12-11 | ALLO | -0.11 | -9.56 | 11.71 |
| 2025-12-12 | ALLO | -0.11 | -9.56 | 11.71 |
| 2025-12-15 | ALLO | -0.06 | -9.56 | 11.65 |
| 2025-12-16 | ALLO | -0.06 | -9.56 | 11.65 |
| 2025-12-17 | ALLO | -0.06 | -9.56 | 11.65 |
| 2025-12-18 | ALLO | -0.06 | -9.56 | 11.65 |
| 2025-12-19 | ALLO | -0.06 | -9.56 | 11.65 |
| 2025-12-22 | ALLO | -0.06 | -9.57 | 11.65 |
| 2025-12-23 | ALLO | -0.06 | -9.57 | 11.65 |
| 2025-12-26 | ALLO | -0.06 | -9.57 | 11.26 |
| 2025-12-29 | ALLO | -0.06 | -9.58 | 11.26 |
| 2025-12-30 | ALLO | -0.06 | -9.58 | 11.26 |
| 2025-12-31 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-02 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-05 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-06 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-07 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-08 | ALLO | -0.06 | -9.58 | 11.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.22
Avg. EPS Est. Next Quarter
-0.22
Insider Transactions
-0.06
Institutional Transactions
-9.58
Beta
0.6
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
23
Sentiment Score
44
Actual DrawDown %
96.2
Max Drawdown 5-Year %
-97.6
Target Price
7.6
P/E
Forward P/E
PEG
P/S
P/B
1.05
P/Free Cash Flow
EPS
-0.98
Average EPS Est. Cur. Y
-0.94
EPS Next Y. (Est.)
-0.91
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.14
Return on Equity vs Sector %
-94.5
Return on Equity vs Industry %
-79.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.09
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading